Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Chimeric Therapeutics Ltd. ( (AU:CHM) ).
Chimeric Therapeutics has secured approximately A$4.0 million in non-dilutionary funding from a US-based philanthropic family office to advance its CHM CDH17 CAR-T cell therapy. This funding supports the ongoing Phase 1/2 clinical trial aimed at determining the recommended Phase 2 dose and evaluating the safety and response rate in patients with advanced gastrointestinal cancers. The investment underscores the potential of CHM CDH17, a novel therapy targeting CDH17, which is linked to poor prognosis in common gastrointestinal cancers.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics is an Australian clinical stage cell therapy company specializing in innovative cancer treatments. The company focuses on developing and commercializing first-in-class autologous CAR-T cell therapies and best-in-class allogeneic NK cell therapies, with a diversified portfolio targeting various oncology disease areas.
Average Trading Volume: 4,603,630
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$11.17M
See more data about CHM stock on TipRanks’ Stock Analysis page.